公开(公告)号：WO2012166617A3

公开(公告)日：2014-05-08

申请号：PCT/US2012039628

申请日：2012-05-25

Applicant: CYTOCURE LLC ,  GEN HOSPITAL CORP ,  HAGGERTY TIMOTHY J ,  KURNICK JAMES T ,  DUNN IAN S

Inventor： HAGGERTY TIMOTHY J ,  KURNICK JAMES T ,  DUNN IAN S

IPC: A61K39/395 ,  A61K38/21 ,  A61P35/00

CPC classification number: A61K35/14 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/4965 ,  A61K35/15 ,  A61K35/17 ,  A61K38/215 ,  A61K38/217 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/3053 ,  A61K2300/00

Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-&bgr; receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.

Abstract translation: 本发明的特征在于单独给予HSP90抑制剂，OBAA，氟桂灵，阿奇非丁，丹那卡他敏，丹曲林或其类似物的方法，组合物和试剂盒，或与例如TAA，抗原结合支架（ 例如特异于TAA，细胞（例如靶向癌细胞的白细胞）的抗体，可溶性T细胞受体或嵌合受体）和/或IFN-和bgr; 受体激动剂或IFN-γ受体激动剂，用于治疗癌症。

公开(公告)号：WO2004087941A1

公开(公告)日：2004-10-14

申请号：PCT/US2003/004786

申请日：2003-02-18

Applicant: THE GENERAL HOSPITAL CORPORATION ,  KURNICK, James, T. ,  DURDA, Paul, J.

Inventor： KURNICK, James, T. ,  DURDA, Paul, J.

IPC: C12Q1/00

CPC classification number: C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158

Abstract: This invention relates to methods for identifying agents that modulate expression of tumor-associated antigens in tumor cells. The invention also relates to agents and pharmaceutical compositions containing such agents that modulate expression of tumor-associated antigens in tumor cells. The invention, therefore, is particularly useful, inter alia, for treating subjects with autologous, solid tumors having cells that express, or that can be induced to express, tumor-associated antigens. One category of materials according to the invention is tumor-antigen expression up-regulating agents. These agents include modulators of the MAPK/ERKL signaling cascade, and more specifically modulators of MEK1/2 and ERK1/2 activity.

Abstract translation: 本发明涉及用于鉴定调节肿瘤细胞中肿瘤相关抗原表达的试剂的方法。 本发明还涉及含有调节肿瘤细胞中肿瘤相关抗原表达的试剂和药物组合物。 因此，本发明尤其可用于治疗具有表达或可诱导表达肿瘤相关抗原的细胞的自体，实体瘤的受试者。 根据本发明的一类材料是肿瘤 -​​ 抗原表达上调剂。 这些试剂包括MAPK / ERKL信号级联的调节剂，更具体地说是MEK1 / 2和ERK1 / 2活性的调节剂。

公开(公告)号：WO2004019886A3

公开(公告)日：2004-09-10

申请号：PCT/US0327125

申请日：2003-08-29

Applicant: CYTOCURE LLC ,  DURDA PAUL J ,  KURNICK JAMES T ,  DUNN IAN S

Inventor： DURDA PAUL J ,  KURNICK JAMES T ,  DUNN IAN S

IPC: A61B19/00 ,  A61K20060101 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395 ,  C07K16/30 ,  G01N33/50

CPC classification number: C07K16/3053 ,  A61K35/15 ,  A61K38/215 ,  A61K39/0011 ,  A61K2039/55522 ,  G01N33/5011 ,  A61K2300/00

Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-beta receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.

Abstract translation: 本发明提供调节肿瘤抗原相关（TAA）表达的方法以及调节TAA表达以治疗肿瘤的方法。 更具体地，本发明提供增加针对肿瘤细胞的免疫应答的方法。 方法包括向患者施用一定量的IFN-β受体激动剂和足以增加针对肿瘤细胞的免疫应答的肿瘤相关抗原（TAA）。

公开(公告)号：WO0136472A3

公开(公告)日：2002-01-10

申请号：PCT/US0031511

申请日：2000-11-15

Applicant: GEN HOSPITAL CORP ,  KURNICK JAMES T

Inventor： KURNICK JAMES T

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/47 ,  C07K16/18 ,  C12N5/09 ,  C12P21/02 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  C07K16/30

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0693 ,  G01N33/5011

Abstract: This invention relates to methods and compositions for the treatment of tumors. In particular, the invention relates to methods and agents for the treatment of tumors expressing a tumor-antigen [also known as a tumor-associated antigen ( TAA ), lineage specific, differentiation, or self-antigens], and more specifically to methods and agents for the treatment of melanomas expressing the Melan-A/MART-1 antigen. The invention also relates to methods for identifying agents that regulate expression of tumor-antigens .

Abstract translation: 本发明涉及治疗肿瘤的方法和组合物。 具体而言，本发明涉及治疗表达肿瘤抗原[也称为肿瘤相关抗原（TAA））的肿瘤的方法和药剂，谱系特异性的， 分化或自身抗原]，并且更具体地涉及用于治疗表达Melan-A / MART-1抗原的黑素瘤的方法和药剂。 本发明还涉及鉴定调节肿瘤抗原表达的试剂的方法。

公开(公告)号：WO2012166617A2

公开(公告)日：2012-12-06

申请号：PCT/US2012/039628

申请日：2012-05-25

Applicant: CYTOCURE LLC ,  THE GENERAL HOSPITAL CORPORATION ,  HAGGERTY, Timothy, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

Inventor： HAGGERTY, Timothy, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

IPC: A61K39/395

CPC classification number: A61K35/14 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/4178 ,  A61K31/495 ,  A61K31/4965 ,  A61K35/15 ,  A61K35/17 ,  A61K38/215 ,  A61K38/217 ,  A61K39/395 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/3053 ,  A61K2300/00

Abstract: The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.

Abstract translation: 本发明的特征在于单独给予HSP90抑制剂，OBAA，氟桂灵，阿奇非丁，丹那卡他敏，丹曲林或其类似物的方法，组合物和试剂盒，或与例如TAA，抗原结合支架（ 例如针对TAA，细胞（例如靶向癌细胞的白血细胞）和/或IFN-β受体激动剂或IFN-β受体激动剂特异性的抗体，可溶性T细胞受体或嵌合受体， ？ 受体激动剂，用于治疗癌症。

公开(公告)号：WO2004019886A2

公开(公告)日：2004-03-11

申请号：PCT/US2003/027125

申请日：2003-08-29

Applicant: CYTOCURE LLC ,  DURDA, Paul, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

Inventor： DURDA, Paul, J. ,  KURNICK, James, T. ,  DUNN, Ian, S.

IPC: A61K

CPC classification number: C07K16/3053 ,  A61K35/15 ,  A61K38/215 ,  A61K39/0011 ,  A61K2039/55522 ,  G01N33/5011 ,  A61K2300/00

Abstract: The invention provides methods of modulating tumor antigen associated (TAA) expression, and methods of modulating TAA expression in order to treat a tumor. More particularly, the invention provides methods of increasing an immune response against tumor cell. Methods include administering to a subject with a tumor an amount of IFN-β receptor agonist and tumor associated antigen (TAA) sufficient to increase an immune response against the tumor cell.

Abstract translation: 本发明提供了调节肿瘤抗原相关（TAA）表达的方法以及调节TAA表达以治疗肿瘤的方法。 更具体地说，本发明提供了增加针对肿瘤细胞的免疫应答的方法。 方法包括向患有肿瘤的受试者施用足以增加针对肿瘤细胞的免疫应答的量的IFN-β受体激动剂和肿瘤相关抗原（TAA）。

公开(公告)号：WO0136461A3

公开(公告)日：2002-01-17

申请号：PCT/NL0000835

申请日：2000-11-15

Applicant: ACADEMISCH ZIEKENHUIS LEIDEN ,  DEN ELSEN PETRUS JOSEPHUS VAN ,  KURNICK JAMES T

Inventor： VAN DEN ELSEN PETRUS JOSEPHUS ,  KURNICK JAMES T

IPC: A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/47 ,  C07K16/18 ,  C12N5/09 ,  C12P21/02 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50 ,  C07K16/30

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0693 ,  G01N33/5011

Abstract: This invention relates to methods and compositions for the treatment of tumors. In particular, the invention relates to methods and agents for the treatment of tumors expressing a tumor-antigen [also known as a tumor-associated antigen ( TAA ), lineage specific, differentiation, or self-antigens], and more specifically to methods and agents for the treatment of melanomas expressing the Melan-A/MART-1 antigen. The invention also relates to methods for identifying agents that regulate expression of tumor-antigens .

Abstract translation: 本发明涉及治疗肿瘤的方法和组合物。 特别地，本发明涉及用于治疗表达肿瘤抗原的肿瘤的方法和试剂[也称为肿瘤相关抗原（TAA）），谱系特异性， 分化或自身抗原]，更具体地涉及用于治疗表达Melan-A / MART-1抗原的黑素瘤的方法和试剂。 本发明还涉及用于鉴定调节肿瘤抗原表达的试剂的方法。

公开(公告)号：WO2001035903A2

公开(公告)日：2001-05-25

申请号：PCT/US2000031508

申请日：2000-11-15

Applicant: THE GENERAL HOSPITAL CORPORATION ,  RIJKSUNIVERSITEIT LEIDEN ,  KURNICK, James, T. ,  VAN DEN ELSEN, Peter, J.

Inventor： THE GENERAL HOSPITAL CORPORATION ,  RIJKSUNIVERSITEIT LEIDEN

IPC: A61K

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0693 ,  G01N33/5011

Abstract: This invention relates to methods and compositions for the treatment of tumors. In particular, the invention relates to methods and agents for the treatment of tumors expressing a tumor-antigen [also known as a tumor-associated antigen TAA , lineage specific, differentiation, or self-antigens], and more specifically to methods and agents for the treatment of melanomas expressing the Melan-A/MART-1 antigen. The invention also relates to methods for identifying agents that regulate expression of tumor-antigens .

Abstract translation: 本发明涉及治疗肿瘤的方法和组合物。 特别地，本发明涉及用于治疗表达肿瘤抗原的肿瘤的方法和试剂（也称为与肿瘤相关的抗原TAA ，谱系特异性，分化， 或自身抗原]，更具体地涉及用于治疗表达Melan-A / MART-1抗原的黑素瘤的方法和试剂。 本发明还涉及用于鉴定调节肿瘤抗原表达的试剂的方法。